Table 1. Mean (one standard deviation) plasma canrenone and 7-α-thiomethyl spironolactone (TMS) concentration following treatment with spironolactone at either 2 mg/kg/day or 4mg/kg/day for seven days at T1 (immediately prior to spironolactone dosing) and T2 (5 hours post-spironolactone dose) in 10 healthy purpose-bred Beagle dogs using a cross-over study design.

The range of plasma canrenone and TMS at each timepoint following spironolactone treatment is also reported.

Spironolactone Metabolite	2 mg/kg/day D7 @ T1	2 mg/kg/day D7 @ T2	2 mg/kg/day D28 @ T1	2 mg/kg/day D28 @ T2
Canrenone (ng/mL)	6.2 (1.9) (range: 3.3–8.0)	42.1 (6.5) (range: 33.0–50.0)	12.2 (4.1) (range: 6.2–17.1)	38.9 (5.1) (range: 32.2–45.1)
TMS (ng/mL)	5.9 (2.7) (range: < 2.0–9.7)	62.4 (11.4) (range: 43.6–74.7)	7.8 (2.0) (range: 5.5–10.9)	66.2 (21.3) (range: 37.0–87.5)
Spironolactone Metabolite	4 mg/kg/day D7 @ T1	4 mg/kg/day D7 @ T2	4 mg/kg/day D28 @ T1	4 mg/kg/day D28 @ T2
Canrenone (ng/mL)	14.8 (10.5) (range: 8.8–33.4)	76.3 (16.0) (range: 58.6–91.6)	11.7 (5.0) (range: 5.6–19.5)	61.8 (36.5) (range: 13.4–99.0)
TMS (ng/mL)	14.2 (12.2) (range: 5.3–35.1)	150.4 (62.2) (range: 82.1–234.0)	8.5 (4.1) (range: 3.9–12.8)	103.3 (44.6) (range: 77.6–170.0)